Sertraline and Urinary Frequency
Sertraline can cause urinary incontinence, not urinary frequency, and this adverse effect is well-documented in both FDA labeling and clinical research, particularly in children, adolescents, and elderly patients.
Evidence from FDA Drug Labeling
The official FDA-approved prescribing information for Zoloft (sertraline) explicitly lists urinary incontinence as a common side effect in children and adolescents 1. This is critical information directly from the drug label, which takes precedence in establishing known adverse effects.
Clinical Research Findings
Urinary Incontinence vs. Frequency
The distinction between urinary incontinence and urinary frequency is important:
- Urinary incontinence (involuntary loss of urine) is the documented adverse effect of sertraline
- Urinary frequency (increased number of voids) has not been consistently demonstrated
A retrospective study of 13,531 first-time SSRI users found that sertraline exposure was associated with an increased risk of urinary incontinence with an adjusted relative risk of 2.76 (95% CI 1.47-5.21) - the highest among all SSRIs studied 2. This translates to approximately 15 extra cases of urinary incontinence per 1000 patients treated per year, with the elderly experiencing 60 extra cases per 1000 patients per year 2.
Nocturnal Urinary Frequency Specifically
Regarding nocturnal urinary frequency specifically, a 2016 study of 316 individuals found no statistically significant difference in nocturnal urinary frequency between those on SSRI/SNRI therapy and controls (0.40 vs 0.34 bathroom visits/night, P = 0.40) 3. Interestingly, sertraline users had higher nocturnal frequency (0.61 visits/night) compared to duloxetine users (0.18 visits/night), suggesting SSRIs may have a different effect than SNRIs 3.
Clinical Mechanism
The mechanism appears to be mediated through 5-HT4 receptors found on the bladder 4. Multiple case reports document dose-dependent urinary incontinence that improves with dose reduction and recurs at higher doses 5, 4.
Clinical Implications
If a patient develops urinary symptoms on sertraline:
- First: Distinguish between incontinence (involuntary loss) versus frequency (increased voids)
- For incontinence: Consider dose reduction, as symptoms show a clear dose-response relationship 5
- Alternative management: Switch to another SSRI with lower risk, or add adjunctive therapy such as solifenacin (anticholinergic) 5
- Higher risk populations: Elderly patients, those on higher doses, and those taking concomitant medications like lithium or beta-blockers 4
Important Caveat
While urinary incontinence is documented, true urinary frequency (simply needing to void more often without incontinence) is not a well-established side effect of sertraline based on the available evidence. The nocturnal frequency study suggests minimal to no effect on frequency specifically 3.